Q4 2021 Results

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Ophthalmology Respiratory & Allergy Oncology: Solid Tumors Hematology Biosimilars Global Health Abbreviations Cosentyx® - IL-17A inhibitor Study Indication Phase Patients Primary Outcome Measures Arms Intervention Target Patients Read-out Milestone(s) Publication NCT03713619 SUNSHINE (CAIN457M2301) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of participants with Hidradenitis Suppurativa clinical response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Patients with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 NCT03713632 SUNRISE (CAIN457M2302) Hidradenitis Suppurativa (HS) Phase 3 471 Proportion of patients with Hidradenitis Suppurativa Clinical Response (HiSCR) Secukinumab 300 mg every 2 weeks Secukinumab 300 mg every 4 weeks Placebo (every 2 weeks) Placebo (every 4 weeks) Subjects with moderate to severe Hidradenitis Suppurativa Primary (week 16): H2-2021; Final: 2022 Study design SHSA 2020; Primary 2022 80 Investor Relations | Q4 2021 Results NOVARTIS | Reimagining Medicine

View entire presentation